CHENGDU OLYMVAX BIOPHARMACEUTICALS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.71 CNY | +1.28% |
|
+0.11% | -44.87% |
| 05-16 | Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials | MT |
| 04-25 | Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 14,513 | 5,621 | 6,417 | 3,538 | - | - |
| Enterprise Value (EV) 1 | 14,513 | 5,621 | 6,417 | 3,538 | 3,538 | 3,538 |
| P/E ratio | 128 x | 211 x | 368 x | 45.8 x | 23.8 x | 20.7 x |
| Yield | - | - | 0.24% | 0.34% | 0.69% | 1.15% |
| Capitalization / Revenue | 29.8 x | 10.3 x | 12.9 x | 5.38 x | 3.28 x | 3.32 x |
| EV / Revenue | 29.8 x | 10.3 x | 12.9 x | 5.38 x | 3.28 x | 3.32 x |
| EV / EBITDA | 115 x | 79.9 x | 192 x | 29.5 x | 20.2 x | - |
| EV / FCF | - | - | - | -505 x | -131 x | 58 x |
| FCF Yield | - | - | - | -0.2% | -0.76% | 1.72% |
| Price to Book | 17.2 x | 6.38 x | 7.05 x | 3.6 x | 3.07 x | 2.95 x |
| Nbr of stocks (in thousands) | 405,265 | 405,265 | 406,158 | 406,158 | - | - |
| Reference price 2 | 35.81 | 13.87 | 15.80 | 8.710 | 8.710 | 8.710 |
| Announcement Date | 22-02-22 | 23-02-27 | 24-02-27 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 320.1 | 487.2 | 547.5 | 496.1 | 658 | 1,079 | 1,067 |
| EBITDA 1 | - | 126.3 | 70.34 | 33.36 | 120 | 175 | - |
| EBIT 1 | - | 101.6 | 41.62 | 3.402 | 59 | 154 | 131 |
| Operating Margin | - | 20.85% | 7.6% | 0.69% | 8.97% | 14.27% | 12.28% |
| Earnings before Tax (EBT) 1 | - | 107.2 | 43.65 | 15.92 | 66 | 157 | 140 |
| Net income 1 | 36.92 | 108 | 26.58 | 17.41 | 79 | 153 | 172 |
| Net margin | 11.53% | 22.16% | 4.85% | 3.51% | 12.01% | 14.18% | 16.12% |
| EPS 2 | - | 0.2804 | 0.0656 | 0.0429 | 0.1900 | 0.3667 | 0.4200 |
| Free Cash Flow 1 | - | - | - | - | -7 | -27 | 61 |
| FCF margin | - | - | - | - | -1.06% | -2.5% | 5.72% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | 35.47% |
| Dividend per Share 2 | - | - | - | 0.0380 | 0.0300 | 0.0600 | 0.1000 |
| Announcement Date | 21-05-18 | 22-02-22 | 23-02-27 | 24-02-27 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | -7 | -27 | 61 |
| ROE (net income / shareholders' equity) | - | 17.7% | 3.1% | 1.95% | 8% | 13.1% | 14.4% |
| ROA (Net income/ Total Assets) | - | 9.13% | 1.97% | 1.08% | 6.6% | 8.4% | - |
| Assets 1 | - | 1,183 | 1,346 | 1,613 | 1,197 | 1,821 | - |
| Book Value Per Share 2 | - | 2.080 | 2.180 | 2.240 | 2.420 | 2.840 | 2.950 |
| Cash Flow per Share 2 | - | 0.1000 | -0.0600 | 0.1100 | 0.1300 | 0.2900 | - |
| Capex 1 | - | 69.7 | 201 | 170 | 79 | 79.7 | 50 |
| Capex / Sales | - | 14.31% | 36.66% | 34.24% | 12.01% | 7.38% | 4.69% |
| Announcement Date | 21-05-18 | 22-02-22 | 23-02-27 | 24-02-27 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.71
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -44.87% | 483M | |
| -2.99% | 89.49B | |
| +2.24% | 40.67B | |
| -12.97% | 33.15B | |
| +61.72% | 26.45B | |
| -20.71% | 14.69B | |
| -7.31% | 12.89B | |
| -12.64% | 11.54B | |
| -42.60% | 11.34B | |
| +4.27% | 8.84B |
- Stock Market
- Equities
- 688319 Stock
- Financials Chengdu Olymvax Biopharmaceuticals Inc.
